Chai Discovery is a frontier AI company that focuses on predicting how biochemical molecules interact. They have a team of experts that hail from the likes of Open AI and Meta. The company aims to transform biology from a science into a precise engineering discipline. They currently partner several high profile venture capital firms and AI labs.

Chai Discovery just secured a funding round to focus on its core innovation, programmable biology. The firm is moving beyond traditional drug discovery, a process that is often slow and susceptible to errors, to a model of “computer-aided-design” for molecules.

The company’s latest generative AI model can design antibodies from scratch (de novo design), with success rates at 100 times higher than previous computational methods. Unlike earlier models that churn out theoretically interesting molecules, Chai’s latest models focus on “developability”, ensuring that molecules have the stability and physical properties of therapeutics. The model also addresses “undruggable targets”, traditionally complex biological targets that are hard to solve.

Chai Discovery accelerates its time to market. It replaces years of lab iteration with high precision computational simulation. Chai aims to reduce the billions spent in bringing drug discoveries to human trials.

The new funding will be used to scale their research, expand their team and develop their molecular design software for commercial use.

Chai Discovery is leveraging massive new investment and “zero-shot” generative AI to transform the pharmaceutical industry, moving from a model of discovery by chance to a model of intentional, high-speed molecular engineering.